

Development of a Novel Multiple Sclerosis Treatment Using the Regulatory T Cell (Treg)-Modulating Peptide KINE-101

KINE SCIENCES



IMMUNOLOGY	Preclinical
Product Type	rProtein
Indication	Multiple Sclerosis (MS)
Target	****
MoA(Mechanism of Action)	Suppression of inflammatory responses through Treg modulation
Competitiveness	<ol style="list-style-type: none"> 1. Immune regulation through Treg activation 2. Blood-brain barrier penetration → suppression of immune cells in the central nervous system 3. Favorable clinical safety profile
Development Stage	Preclinical
Route of Administration	IV or SC

Any unauthorized distribution or reproduction of this material is strictly prohibited.